Restaging MRI Can Predict Survival With Rectal Cancer
By Lori Solomon HealthDay Reporter
TUESDAY, Oct. 29, 2024 -- Restaging magnetic resonance imaging (MRI) can predict organ preservation and survival with rectal cancer, according to a study published online Sept. 3 in Radiology.
Hannah Williams, M.D., from the Memorial Sloan Kettering Cancer Center in New York City, and colleagues evaluated the ability of restaging MRI to predict oncologic outcomes and identify imaging features associated with residual disease after total neoadjuvant therapy (TNT). The analysis included data from 277 participants in the Organ Preservation in Rectal Adenocarcinoma trial, which randomly assigned participants (April 2014 to March 2020) with stages II or III rectal adenocarcinoma to undergo either induction or consolidation TNT.
The researchers found that during a median follow-up of 4.1 years, participants with clinical complete response (cCR) had higher rates of organ preservation versus those with near-complete clinical response (nCR; 65.3 versus 41.6 percent1). Five-year disease-free survival was 81.8, 67.6, and 49.6 percent, respectively, for participants with cCR, nCR, and incomplete clinical response. Overall survival was also predicted by the MRI response category, distant recurrence-free survival, and local regrowth. Among the 266 participants with at least two years of follow-up, 48.5 percent had residual disease. The presence of restricted diffusion (odds ratio, 2.50) and presence of abnormal nodal morphologic features (odds ratio, 5.04) were independently associated with residual disease.
"Now we have a powerful tool to help patients and their doctors predict who would benefit from surgery after initial chemotherapy and radiation and who can likely avoid surgery," coauthor Arun Krishnaraj, M.D., from the University of Virginia in Charlottesville, said in a statement.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Odds of Advanced Cancer, Breast Cancer Death Lower in Screen-Detected Disease
THURSDAY, June 5, 2025 -- For patients aged 40 years or older, screen-detected breast cancer is associated with lower odds of advanced cancer, mastectomy, and breast...
ASCO: Durvalumab Plus FLOT Beneficial for Resectable Gastric, GE Junction Cancer
THURSDAY, June 5, 2025 -- For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel...
Cardiorespiratory Effects of Smoke Fine Particulate Matter From Wildfires Can Persist for Months
THURSDAY, June 5, 2025 -- The cardiorespiratory effects of smoke fine particulate matter (PM2.5), a primary wildfire emission that can spike for months after a wildfire begins...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.